CIBC World Markets’s Pyxis Oncology PYXS Stock Holding History

CIBC World Markets’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,945	Closed	-$10.7K	–	1849
2025 Q1	$10.7K	Buy	+10,945	New	+$14.6K	﹤0.01%	1825

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC World Markets's PYXS Position: Q2 2025 in Review

CIBC World Markets sold out of Pyxis Oncology (PYXS) in Q2 2025, closing a stake of 10,945 shares — an estimated $10.7K sold.

CIBC World Markets first reported a position in PYXS in Q1 2025 and held it in 1 quarter. The position peaked at $10.7K in Q1 2025. 74 funds tracked by Wall St. Rank hold PYXS as of Q2 2025.

CIBC World Markets reported no remaining Pyxis Oncology position as of Q2 2025 after selling out during the quarter.
CIBC World Markets sold 10,945 Pyxis Oncology shares in Q2 2025, an estimated $10.7K.
CIBC World Markets first reported a position in Pyxis Oncology in Q1 2025 and held it in 1 quarter.
CIBC World Markets's Pyxis Oncology position peaked at $10.7K in Q1 2025.
74 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.